Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer
Status:
Completed
Trial end date:
2021-01-01
Target enrollment:
Participant gender:
Summary
The investigators design a prospective clinical study to explore the efficacy and safety of
apatinib plus camrelizumab in pretreated patients with advanced biliary tract malignant
tumors and to analyze potential biomarkers of therapeutic response.